Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Conflicts of interest
3. Learning objectives
4. Benefits of clear asthma management strategy
5. GINA 2006: levels of asthma control (1)
6. Asthma management continuum
7. Asthma control in Canada
8. GINA 2006: levels of asthma control (2)
9. Simplified management based upon control
10. Initial treatment in mild asthma
11. Early intervention with budesonide
12. Compliance to ICS therapy can prevent deaths
13. Exacerbations requiring oral steroids
14. Initial treatment of asthma
15. Add-on therapies
16. The risk:benefit ratios of ICS
17. Available ICS + LABA single-inhaler combinations
18. Well controlled asthma with sustained treatment
19. The STAY study
20. STAY: study design
21. SMART increased time to severe exacerbation
22. Severe exacerbations
23. Need for systemic steroids
24. MF/F therapy delayed time to deterioration
25. Asthma control: current control and future risk
26. JACI 2010 - design
27. JACI 2010 - results
28. Fixed dose versus SMART
29. Exacerbations and sputum eosinophil counts
30. Sputum eosinophil counts: RCT design
31. Current control and future risk
32. A window of opportunity
33. The people in your practice
34. Many switched/discontinued maintenance therapy
35. Acute treatment for asthma in past year
36. Stopped taking controller in past year
37. Attitudes about asthma and its treatment
38. Actual and perceived asthma control
39. Family physicians' knowledge of asthma control
40. Asthma control: a comprehensive concept
41. Strategies to engage patients for better control
42. Asthma exacerbations increase future risk
43. Future exacerbations and recent exacerbations
44. Asthma exacerbations association with costs
45. Lung function by asthma and smoking status
46. Factors contributing to airway remodeling
47. Loss of lung function and severe exacerbations
48. Anti-IgE omalizumab
49. Reduction in asthma exacerbations
50. Time to first asthma exacerbation
51. Criteria for Omalizumab administration
52. Blockbuster drug for asthma
53. Self management effect on hospitalizations
54. Effect of optimal self management on ED visits
55. Asthma education and monitoring (1)
56. Asthma education and monitoring (2)
57. Asthma education
58. Conclusions
59. Acknowledgment

Topics Covered

• Importance of reviewing patient's history
• Identification of potential environmental factors
• Patients with uncontrolled asthma may require anti-inflammatory medications with inhaled corticosteroids (ICS) being the standard treatment
• Asthmatics on ICS with uncontrolled asthma may require adjunct therapy such as a long acting beta agonist and or a leukotriene antagonist
• Education program and written action plan

Links

Series:

• Advances in Asthma

Categories:

• Clinical Medicine
• Diseases, Disorders & Treatments

Therapeutic Areas:

• Immunology & Inflammation
• Respiratory Diseases

Talk Citation

Publication History

• Published on January 31, 2013

Financial Disclosures

• Prof. Mark Fitzgerald has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.